Wayne Critchley

Senior Associate


Wayne Critchley is Senior Associate with Global Public Affairs’ Health & Life Sciences practice, providing counsel to leading biopharmaceutical and medical device corporations and associations along with other health policy stakeholders. Wayne has a long track record of success as a senior executive with over twenty years of experience in government departments, boards and agencies dealing primarily with issues that impact the pharmaceutical sector. He served as Executive Director of the Patented Medicine Prices Review Board from 1990 to 2005 and as a Vice President of the Canadian Agency for Drugs and Technologies in Health in 2009. From 2007-2009, he was a partner in one of Canada’s leading law firms. Wayne is widely recognized as an expert in pharmaceutical pricing, reimbursement and market access and is regularly called upon to write and present on Canadian pharmaceutical issues. Wayne served as Chair of the Canadian Organization for Rare Disorders from 2015-2019 and currently serves on the Board of Directors of the Macdonald-Laurier Institute. He is also active with the Canadian Club of Ottawa and served as President from 2012-2013.

All Sessions by Wayne Critchley

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020

11:30 am

11:30 am

Keynote Panel Discussion:

Inform your Market Access Strategy with Cross-Border Perspectives on CUSMA, Affordable Drug Prices and Access to Prescription Medicine during Covid-19 and Beyond

One of the consequences of Covid-19 is the problem many people have accessing prescription medication in both Canada and the U.S. because of unemployment and escalating drug costs.  Both Canada and the U.S. have taken steps to address rising costs, so far with limited success.  CUSMA will also have an impact on access going forward.  Gain key insights on:

  • The impact CUSMA may have on IP and Canada’s listing on the ‘Watch List’ of the Office of the U.S. Trade Representative
  • Canada’s future prospects of gaining access to vaccines for Covid-19
  • Progress of drug price containment initiatives of both Canada and the U.S.

Sharpen your North American market access strategies with key insights on cross-border issues